Enhancement of Ambulatory Glucose Profile for Decision Assistance and Treatment Adjustments
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces "CGM Trace," a platform enhancing ambulatory glucose profile (AGP) analysis with new metrics and graphs. It improves interpretation of continuous glucose monitoring (CGM) data for better diabetes management.
Area Of Science
- Endocrinology and Diabetes Technology
- Data Science in Healthcare
Background
- Ambulatory Glucose Profile (AGP) analysis faces challenges due to insufficient statistical metrics and complex graphical representations, hindering interpretation of glucose variability.
- Existing AGP graphs often obscure temporal patterns and fluctuations, making it difficult for clinicians to extract actionable insights for patient care.
Purpose Of The Study
- To develop a decision-assistance platform that overcomes the limitations of traditional AGP interpretation.
- To create a system that provides insightful metrics and graphical representations for enhanced understanding of continuous glucose monitoring (CGM) data.
Main Methods
- Development of 20 novel findings derived from decision rules combining AGP and additional statistical metrics to identify hyperglycemia and hypoglycemia patterns.
- Implementation of the
- CGM Trace
- webpage featuring an interactive interface for data visualization and a dedicated
- Findings
- tab for clinicians.
- Validation of findings using multivariate analysis of variance (MANOVA) on data from 67 patients (15 clinical, 52 public).
Main Results
- The
- CGM Trace
- platform provides insightful metrics and graphical representations for user glucose data analysis.
- A statistically significant correlation (p < 0.05) was established between the developed findings and CGM metrics via MANOVA.
- The system successfully summarized glycemic control for patients, aiding endocrinologists' understanding.
Conclusions
- The proposed
- CGM Trace
- work offers a deeper understanding of CGM data by enhancing AGP reports.
- The platform provides clinicians with insightful information and identifies hidden patterns, facilitating improved treatment adjustments and better diabetes management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...